Scarica l'app Stockscreener
4.99
15.84%
0.76
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Altimmune Inc Borsa (ALT) Ultime notizie
Altimmune Announces Multiple Presentations at Upcoming American - GuruFocus
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions - The Manila Times
Breakthrough GLP-1/Glucagon Drug Pemvidutide Reveals Multiple Cardiometabolic Benefits in New Clinical Data - Stock Titan
Kalkine : Altimmune’s Role in NASDAQ Composite Amid Biotech Sector Momentum - Kalkine Media
Altimmune, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire
Two Sigma Advisers LP Sells 22,700 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Nuveen Asset Management LLC Has $1.56 Million Stock Position in Altimmune, Inc. (NASDAQ:ALT) - Defense World
BNP Paribas Financial Markets Sells 33,984 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Stifel analysts reaffirm Altimmune stock rating with $18 price target By Investing.com - Investing.com South Africa
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential - Seeking Alpha
Stifel analysts reaffirm Altimmune stock rating with $18 price target - Investing.com India
Altimmune, Inc. (NASDAQ:ALT) Shares Bought by ProShare Advisors LLC - Defense World
Altimmune, Inc. (NASDAQ:ALT) Stock Holdings Increased by Millennium Management LLC - Defense World
Investors who lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class ActionALT - ACCESS Newswire
Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. (NASDAQ:ALT) Shares Bought by Deutsche Bank AG - Defense World
Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com India
Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook - Investing.com
FY2029 EPS Estimate for Altimmune Decreased by Analyst - Defense World
Wall Street Zen Upgrades Altimmune (NASDAQ:ALT) to “Hold” - Defense World
ALT Hosts Virtual Meeting to Discuss Strategic Developments | ALT Stock News - GuruFocus
Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Northern Trust Corp - Defense World
Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential - MSN
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - AOL.com
Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On? - Benzinga
Altimmune begins phase 2 trial for AUD treatment By Investing.com - Investing.com South Africa
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluati - GuruFocus
Altimmune (ALT) Begins Phase 2 Trial for Pemvidutide in Treating Alcohol Use Disorder | ALT Stock News - GuruFocus
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder - marketscreener.com
Altimmune begins phase 2 trial for AUD treatment - Investing.com
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) - The Manila Times
Breakthrough AUD Drug Enters Phase 2 Trial: New Hope for 28 Million US Patients With Alcohol Use Disorder - Stock Titan
HC Wainwright Has Strong Forecast for Altimmune Q2 Earnings - Defense World
William Blair Estimates Altimmune’s Q2 Earnings (NASDAQ:ALT) - Defense World
Price T Rowe Associates Inc. MD Acquires 4,158 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
B. Riley Issues Positive Estimate for Altimmune Earnings - Defense World
(ALT) Proactive Strategies - news.stocktradersdaily.com
Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway - MSN
Baird Financial Group Inc. Takes Position in Altimmune, Inc. (NASDAQ:ALT) - The AM Reporter
Stifel Financial Corp Sells 4,649 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Call Transcript - Insider Monkey
Voya Investment Management LLC Decreases Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased - MSN
Piper Sandler maintains Altimmune stock with $25 target - Investing.com Australia
Piper Sandler maintains Altimmune stock with $25 target By Investing.com - Investing.com Nigeria
Altimmune to Participate at Two Upcoming Investor Conferences | - GuruFocus
Altimmune to Participate at Two Upcoming Investor Conferences | ALT Stock News - GuruFocus
Altimmune to Participate at Two Upcoming Investor Conferences - The Manila Times
Altimmune Sets Double Conference Appearance: HC Wainwright and Jefferies Healthcare Events Coming Up - Stock Titan
Altimmune’s 2025 Q1 Results Highlight Clinical Progress - TipRanks
Raymond James Financial Inc. Invests $88,000 in Altimmune, Inc. (NASDAQ:ALT) - Defense World
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):